<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE334nnn/GSE334757/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Genome binding/occupancy profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE334757</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Locus-selective targeting of the oncogenic fusion EWSR1-FLI1 in Ewing Sarcoma by CRISPR/dCas9 silencers</name><description>Despite the revolutionary impact of genome engineering tools in medicine, the safe and effective intracellular delivery of CRISPR remains a major obstacle for clinical applications. Here, we utilize precision molecular targeting and delivery strategies based on CRISPR/dCas9 systems adapted for epigenetic repression (dCas9-KRAB) to silence oncogenic drivers with high selectivity. As proof-of-principle, we target the EWSR1-FLI1 translocation, which encodes a chimeric and hard-to-drug oncogenic transcription factor driving approximately 85% of the cases of Ewing Sarcoma (EWS)-an aggressive childhood malignancy. We describe the development of a programmable non-viral polymeric system for the delivery of dCas9-KRAB as ribonucleoprotein (RNP) payloads for selective EWSR1-FLI1 repression. We demonstrate highly efficient intracellular delivery of RNPs loaded in polyamide-amine (PAMAM) polymers functionalized by guanidino groups, resulting in robust silencing of EWSR1-FLI1 both in established cell line xenografts and in EWS-related patient-derived xenografts (PDXs) of EWS. We show that silencing of EWSR1–FLI1 is accompanied by potent anti-tumor effects. To our knowledge, this represents the first effective non-viral platform for in vivo delivery of dCas9-KRAB/RNPs, which could be adapted for the repression of any oncogene. We further outline dCas9/RNP formulations for future therapeutic applications to treat poor-prognosis cancers driven by hard-to-drug oncogenes.</description><dates><publication>2026/09/03</publication></dates><accession>GSE334757</accession><cross_references><GSM>GSM9796708</GSM><GSM>GSM9796707</GSM><GSM>GSM9796706</GSM><GSM>GSM9796705</GSM><GSM>GSM9796709</GSM><GSM>GSM9796670</GSM><GSM>GSM9796692</GSM><GSM>GSM9796691</GSM><GSM>GSM9796690</GSM><GSM>GSM9796696</GSM><GSM>GSM9796674</GSM><GSM>GSM9796673</GSM><GSM>GSM9796695</GSM><GSM>GSM9796694</GSM><GSM>GSM9796672</GSM><GSM>GSM9796693</GSM><GSM>GSM9796671</GSM><GSM>GSM9796678</GSM><GSM>GSM9796699</GSM><GSM>GSM9796677</GSM><GSM>GSM9796676</GSM><GSM>GSM9796698</GSM><GSM>GSM9796697</GSM><GSM>GSM9796675</GSM><GSM>GSM9796679</GSM><GSM>GSM9796681</GSM><GSM>GSM9796680</GSM><GSM>GSM9796685</GSM><GSM>GSM9796684</GSM><GSM>GSM9796683</GSM><GSM>GSM9796682</GSM><GSM>GSM9796667</GSM><GSM>GSM9796689</GSM><GSM>GSM9796700</GSM><GSM>GSM9796688</GSM><GSM>GSM9796666</GSM><GSM>GSM9796687</GSM><GSM>GSM9796665</GSM><GSM>GSM9796686</GSM><GSM>GSM9796704</GSM><GSM>GSM9796703</GSM><GSM>GSM9796702</GSM><GSM>GSM9796669</GSM><GSM>GSM9796668</GSM><GSM>GSM9796701</GSM><GPL>24676</GPL><GSE>334757</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>